Literature DB >> 10772436

Possible hypothyroidism associated with quetiapine.

B M Feret1, C F Caley.   

Abstract

OBJECTIVE: To report a case of hypothyroidism occurring after the addition of quetiapine to an existing drug regimen. CASE
SUMMARY: A 46-year-old African-American woman diagnosed with schizoaffective disorder, bipolar type, and a four-year history of successfully treated hyperthyroidism, was suboptimally responsive to olanzapine treatment. Transition from olanzapine to quetiapine was initiated and, approximately two months after adding quetiapine to a standing pharmacotherapeutic regimen, the patient developed an elevated thyroid-stimulating hormone (TSH) concentration of 8.45 microU/L. A diagnosis of hypothyroidism was subsequently made, treatment with levothyroxine was initiated, and the patient's thyroid function became stable. DISCUSSION: Drug induced hypothyroidism is known to occur with several medications. Quetiapine is an atypical antipsychotic with the potential to decrease thyroid hormone concentrations in some patients; this effect may be dose related. Despite this known adverse effect, the manufacturer of quetiapine reports that elevated TSH concentrations and subsequent treatment with thyroid hormone supplementation have occurred only rarely. We report the development of hypothyroidism in a patient who had previously received successful radioactive iodine treatment for hyperthyroidism in 1994, but who had no detected thyroid abnormalities until treatment with quetiapine was started four years later.
CONCLUSIONS: Patients with compromised thyroid function who receive treatment with quetiapine may develop hypothyroidism. Appropriate care for these patients may include an increased awareness of possible hypothyroidism and consideration of thyroid function monitoring.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772436     DOI: 10.1345/aph.19186

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Authors:  Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-05

2.  Quetiapine-induced hypothyroidism.

Authors:  Sriram Ramaswamy; Zakaria Siddiqui; Sahdev Saharan; Teri L Gabel; Subhash C Bhatia
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

3.  Thyroid Function and Ultrasonography Abnormalities in Lithium-Treated Bipolar Patients: A Cross-sectional Study with Healthy Controls.

Authors:  Özlem Kuman Tunçel; Fisun Akdeniz; Süha Süreyya Özbek; Gülgün Kavukçu; Gökçen Ünal Kocabaş
Journal:  Noro Psikiyatr Ars       Date:  2017-06-01       Impact factor: 1.339

Review 4.  The bidirectional relation between psychiatric disorders with selected cardiovascular and endocrinal diseases: an Egyptian perspective.

Authors:  Tarek Okasha; Ash-Shayma Radwan
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

5.  Intoxication after extreme oral overdose of quetiapine to attempt suicide: pharmacological concerns of side effects.

Authors:  C Müller; H Reuter; C Dohmen
Journal:  Case Rep Med       Date:  2010-01-03

6.  Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort.

Authors:  Christophe G Lambert; Aurélien J Mazurie; Nicolas R Lauve; Nathaniel G Hurwitz; S Stanley Young; Robert L Obenchain; Nicolas W Hengartner; Douglas J Perkins; Mauricio Tohen; Berit Kerner
Journal:  Bipolar Disord       Date:  2016-05       Impact factor: 6.744

7.  Thyroid functions in patients with bipolar disorder and the impact of quetiapine monotherapy: a retrospective, naturalistic study.

Authors:  Chao Li; Jianbo Lai; Tingting Huang; Yuqing Han; Yanli Du; Yi Xu; Shaohua Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-09       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.